文献速递基础与转化研究流行病学与生物统计

贝叶斯非线性联合模型的中介分析:评估肿瘤生长动力学与总生存之间的治疗因果路径

Mediation Analysis With Bayesian Nonlinear Joint Models: Evaluation of the Treatment Causal Pathways Between Tumor Growth Kinetics and Overall Survival.
PubMed 文献 · Stat Med · 2026-01-01

该研究开发了一个贝叶斯联合建模框架用于中介分析,量化肿瘤大小动态在治疗对总生存(OS)效应中的中介程度。模型整合了描述肿瘤生长抑制(TGI)的非线性纵向子模型与参数生存模型,支持多种肿瘤大小与生存之间的生物学连接函数。应用于IMBrave150 III期研究提示,治疗效应的中介比例随时间变化,肿瘤动态部分但非完全捕获治疗作用机制。

要点

  • 贝叶斯联合模型可量化肿瘤大小动态对治疗-OS效应的中介比例。
  • 中介比例随时间变化,肿瘤动态仅部分解释治疗作用机制。
  • 该框架有助于验证肿瘤大小作为生存替代终点。

核心结论

  • 肿瘤大小动态部分但非完全中介治疗对总生存的效应,中介比例随时间变化。

研究设计与样本

  • 贝叶斯分层联合模型,整合非线性纵向肿瘤生长抑制子模型与参数生存模型。
  • 通过不同中介水平和样本量的模拟评估偏倚、覆盖率和可识别性。
  • 应用于IMBrave150 III期研究。

主要发现

  • IMBrave150应用提示治疗效应的中介比例随时间变化。
  • 肿瘤动态部分但非完全捕获治疗作用机制。

关键数值与推荐

  • 计算了随时间变化的中介比例(PTE)、自然直接效应(NDE)和自然间接效应(NIE)。
  • 模型支持多种肿瘤大小与生存之间的生物学连接函数。
  • 探索了治疗对肿瘤缩小和再生长速率效应的不同参数化。

临床怎么用

  • 该框架可用于肿瘤学中研究中介机制。
  • 可能有助于验证肿瘤大小作为生存的替代终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Understanding the mechanisms through which anti-cancer treatments influence survival is central to improving drug development and evaluation. In this work, we develop a Bayesian joint modeling framework for mediation analysis to quantify the extent to which tumor size dynamics mediate the effect of treatment on overall survival (OS). Our model integrates a nonlinear longitudinal sub-model describing tumor growth inhibition (TGI) with a parametric survival model, and supports several biologically motivated link functions between tumor size and survival. We explore alternative parameterizations of the treatment effect on tumor shrinkage and regrowth rates and assess their impact on mediation quantities. The approach is implemented using a Bayesian hierarchical joint model. Marginal effects are computed to characterize the proportion of treatment effect (PTE), natural direct effect (NDE), and natural indirect effect (NIE) over time. Through simulations under varying mediation levels and sample sizes, we evaluate bias, coverage, and identifiability of mediation quantities. Application to the IMBrave150 Phase III study suggests that the mediated proportion of the treatment effect varies over time, indicating that tumor dynamics partially but not fully capture the treatment mechanism of action. This framework provides a robust tool to investigate mediation mechanisms in oncology and may contribute to the validation of tumor size as a surrogate endpoint for survival.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Kazantzidis G, Mercier F, Rondeau V, et al. Mediation Analysis With Bayesian Nonlinear Joint Models: Evaluation of the Treatment Causal Pathways Between Tumor Growth Kinetics and Overall Survival. Stat Med. 2026. PMID: 42179334. doi:10.1002/sim.70574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。